Previous 10 | Next 10 |
Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Update to include supplemental information and allow additional time to complete regulatory review SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the...
2023-10-19 13:03:05 ET Gainers: WeBuy Global Ltd ( WBUY ) +138% . SeaStar Medical Holding Corp ( ICU ) +36% . Spectral AI MDAI +32% . Palatin Technologies PTN +29% . Mmtec ( MTC ) +29% . Maison Solutions ( MSS ) +26% . Bi...
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled ...
2023-09-28 17:12:16 ET Gainers: Editas Medicine ( NASDAQ: EDIT ) +8% . Marqeta ( MQ ) +3% . Cipher Mining ( CIFR ) +3% . Aclaris Therapeutics ( ACRS ) +2% . Biora Therapeutics ( BIOR ) +2% . Losers: Jaguar Global Grow...
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust clinical device function data SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Biora Th...
2023-09-22 05:00:28 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Every day the market offers us good investment opportunities with a variety of companies. While it can be hard work to investigate all investment opportunities on the market, in this article we...
2023-09-19 08:58:34 ET More on Biora Therapeutics Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Biora sells assets from its former diagnostics unit Biora gains after new patent wins for NaviCap platf...
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 Transaction results in a debt reduction of $50 million for the company On track to fi...
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023 ...
2023-09-06 10:00:10 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...